Lasofoxifene is being advanced in a Phase 3 clinical trial as a targeted therapy for estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated metastatic breast cancer whose disease has progressed after treatment with a CDK4/6 inhibitor. The ongoing ELAINE-3 Phase 3 trial is evaluating lasofoxifene in combination with the CDK4/6 inhibitor, abemaciclib.
ELAINE-3 is a large, randomized, phase 3 study with clinical trial sites across the United States, Europe, Asia-Pacific, Israel, and Canada.
If you are interested in learning more about the study and finding out if you qualify to enroll, visit:
THE ELAINE STUDY
Expanded Access Policy
Patient Resources
Click below to see links. By clicking on the links below, you will leave LeonaBio’s website. LeonaBio does not endorse or update statement on such third-party websites.
- ALS Association
- Alzheimer’s Association
- Alzheimer’s Foundation of America
- American Parkinson’s Disease Association
- International Alliance of ALS/MND Associations
- Lewy Body Dementia Association
- Lewy Body Dementia Resource Center
- National Institute on Aging
- Parkinson’s Foundation
- The Michael J. Fox Foundation for Parkinson’s Research